{"ticker": {"uuid": "f122c6ce-687d-42fb-87f1-05f6399d9ae6", "symbol": "IBRX", "name": "Immunitybio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Are Surging IBRX Retail Debates Hinting at a Deeper Re\u2011rating of ImmunityBio\u2019s Platform?", "summary": "ImmunityBio (IBRX) is awaiting an FDA decision on its drug Anktiva for bladder cancer, with a PDUFA date of January 6, 2027. This regulatory milestone, combined with increasing retail investor interest, is influencing sentiment around the broader immunotherapy platform. The compa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/are-surging-ibrx-retail-debates-hinting-at-a-deeper-rerating", "source_name": "Simply Wall Street", "published_at": "2026-07-15T08:12:57", "published_display": "15 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkM0dEVaZkVaOFBTTUVwN08zVGp3MEJ3QXRkZXFhcVNtRmtCWjRNUTRsYk9oR2pLNFdXR0dDN0w4VlBwWVZQcGpaNkNyX2prMHlyNHNrWWQtV19XYkVRMkxXeVJMSm1UVUdQVFBhbkJUUHVBcGtKalN6WDZMVHZoc2RsRGdtc2Z5U09OY3JjVzZmdUNOZHB5SC1mYjJtOW5zcmlUbXBVRVBlenlIYXVCZHlOMzFMNWtTM1EybFNrdWlmNGs?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T15:39:33+00:00", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Climbs Premarket Despite Investor Stake Cut \u2014 Retail Sees \u2018Imminent\u2019 Global Rollout Catalyst", "summary": "ImmunityBio (IBRX) stock rose in premarket trading even after an institutional investor, Sheets Smith Wealth Management, cut its stake. This climb was driven by retail traders anticipating an imminent global rollout announcement for Anktiva, despite the FDA's ongoing review for b", "url": "https://stocktwits.com/news-articles/markets/equity/ibrx-investor-stake-cut-retail-imminent-global-rollout/cZZbqRKR7pg", "source_name": "Stocktwits", "published_at": "2026-07-14T08:12:50", "published_display": "14 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IBRX Stock Declines \u2014 ImmunityBio Resubmits Anktiva Application To FDA With Additional Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcWp2SVRmUXBHQjYyQVRaOHdNLXhyam5xZDdaOURRQllzZVNqUEdzdU5HRHFIX3J5SkxtVEx0M0ZqMnN3Q3FUVVJMRDBWTzEtYl8xVzB1TFdIcEpvcmNXb0wxSjhwb1VBQW80ODhlM0pNRjRFVUpyUU96bmtwOXplOFRDZThrejZNOWJOMnFyLTFfQ2hvdDNDZkk1b0FiRml3NDdYVWIwOEZMVmF2VW80d3I2T0lFeFcyenJBRDJMUUhKNGlfRjVtQ0YxV2k?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T11:21:30+00:00", "published_display": "13 Jul 2026 11:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk", "summary": "ImmunityBio (IBRX) is gaining attention due to new investment firm positions and speculation about a Q2 revenue surprise and Anktiva label expansion updates. Despite a recent pullback, the stock is up significantly year-to-date and trades below its estimated fair value of $13. Th", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-could-be-37-below-fair-value-following-reve", "source_name": "Simply Wall Street", "published_at": "2026-07-11T18:12:50", "published_display": "11 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise", "summary": "ImmunityBio, Inc. (IBRX) saw its stock rally as institutional investors increased their holdings and retail traders anticipated a strong Q2 revenue surprise, particularly regarding Anktiva sales. Strategic Investment Solutions and Mayflower Financial Advisory significantly raised", "url": "https://es.tradingview.com/news/stocktwits:7cb36081e094b:0-can-ibrx-stock-keep-its-pulse-institutional-investors-buy-in-retail-hopes-for-big-q2-surprise/", "source_name": "TradingView", "published_at": "2026-07-10T18:12:58", "published_display": "10 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout", "summary": "", "url": "https://finance.yahoo.com/m/4a69b719-3b8d-34e5-bd28-3ea282cb0be8/moderna-drops-11%25%2C.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:04:38+00:00", "published_display": "10 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio : IBRX", "summary": "ImmunityBio Inc. (IBRX) is a biotechnology company focused on developing innovative therapies and vaccines for cancers and infectious diseases, including COVID-19 and HIV. The company has a diverse pipeline encompassing immunotherapy, cell therapy, and advanced vaccine technologi", "url": "https://247wallst.com/companies/IBRX/?tpid=1622801&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:08:59", "published_display": "10 Jul 2026 16:08", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares", "summary": "ImmunityBio Inc. (IBRX) stock steadied following the sale of 131,210 shares by director Cheryl Cohen for approximately $1.25 million, though she retains a significant stake. The sale comes as IBRX has experienced a strong multi-week run but faces mounting pressure from clinical t", "url": "https://stockstotrade.com/news/immunitybio-inc-ibrx-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T12:33:00", "published_display": "10 Jul 2026 12:33", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Selecky sells $1.44m in shares", "summary": "ImmunityBio director Christobel Selecky sold 159,478 shares of common stock for $1.44 million on July 1, 2026, after exercising stock options. This sale, conducted via a Rule 10b5-1 trading plan, leaves Ms. Selecky with no direct shares. The company's stock (IBRX) has seen a 305%", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-selecky-sells-144m-in-shares-93CH-4778106", "source_name": "Investing.com", "published_at": "2026-07-07T17:10:22", "published_display": "07 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Cheryl Cohen sells $1.25m in stock", "summary": "ImmunityBio director Cheryl Cohen sold 131,210 shares of the company's common stock for $1.25 million on July 2, 2026, while also acquiring 55,979 shares through stock options. These transactions occurred as ImmunityBio's stock has surged 227% over the past year, though it is con", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-cheryl-cohen-sells-125m-in-stock-93CH-4778108", "source_name": "Investing.com", "published_at": "2026-07-07T16:39:47", "published_display": "07 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-074954528.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:49:54+00:00", "published_display": "07 Jul 2026 07:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-074845085.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:48:45+00:00", "published_display": "07 Jul 2026 07:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) director trades 131K shares, exercises 55,979 options", "summary": "ImmunityBio, Inc. Director Cheryl Cohen reported an exercise-and-sale transaction involving the company's common stock. On July 2, 2026, she sold 131,210 shares at a weighted average price of $9.5034 per share under a pre-arranged Rule 10b5-1 trading plan. Simultaneously, Cohen e", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-a9f624c8064f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T04:11:37", "published_display": "07 Jul 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst", "summary": "ImmunityBio (IBRX) shares slipped after an independent director filed to sell over 131,000 shares, valued at $1.2 million, which cooled retail sentiment despite the stock's recent gains. Investors are now focused on the potential FDA label expansion for Anktiva for papillary blad", "url": "https://es.tradingview.com/news/stocktwits:6cac2a63a094b:0-ibrx-stock-slips-overnight-insider-sale-tests-retail-optimism-ahead-of-fda-growth-catalyst/", "source_name": "TradingView", "published_at": "2026-07-06T16:13:29", "published_display": "06 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion Efforts - What's Changed", "summary": "ImmunityBio (IBRX) saw an 8.4% stock increase despite being removed from several Russell value benchmarks. The company's investment narrative is largely tied to the expansion of its cancer drug Anktiva beyond its initial bladder cancer niche, with investors closely watching the F", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-84-after-russell-index-removal-amid-a", "source_name": "Simply Wall Street", "published_at": "2026-07-05T04:09:37", "published_display": "05 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX - ImmunityBio Inc Revenue Breakdown", "summary": "This page provides a detailed financial breakdown for ImmunityBio Inc. (IBRX), including its market capitalization, enterprise value, income, sales, key financial ratios, stock performance metrics, and ownership percentages. The data presented covers various aspects of the compan", "url": "https://finviz.com/stock?t=IBRX&ty=rv&ta=0&p=d", "source_name": "Finviz", "published_at": "2026-07-03T14:40:52", "published_display": "03 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Selecky sells $871k in stock", "summary": "ImmunityBio director Christobel Selecky sold approximately $871,215 worth of common stock on June 29 and 30, 2026, through a pre-arranged trading plan. These sales followed the exercise of stock options to acquire shares at a lower price. Following these transactions, Selecky no ", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-selecky-sells-871k-in-stock-93CH-4771698", "source_name": "Investing.com", "published_at": "2026-07-02T02:14:09", "published_display": "02 Jul 2026 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunitybio Insider Sold Shares Worth $871,216, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-210702469.html", "source_name": "MT Newswires", "published_at": "2026-07-01T21:07:02+00:00", "published_display": "01 Jul 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares", "summary": "ImmunityBio, Inc. director Christobel Selecky exercised stock options for 96,722 shares of Common Stock and subsequently sold all of them in pre-planned, open-market transactions on June 29-30, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 20", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-ac4ed0a9453b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:43", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale", "summary": "A Form 144 filing by ImmunityBio, Inc. (IBRX) disclosed an insider's recent stock activities. The filing detailed an exercise of 1,000 shares settled for cash on June 30, 2026, and a prior 10b5-1 sale by Christobel Selecky of 95,722 shares on June 29, 2026, for gross proceeds of ", "url": "https://www.stocktitan.net/sec-filings/IBRX/144-immunity-bio-inc-sec-filing-e46f90cd886f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:04", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales", "summary": "ImmunityBio, Inc. (IBRX) stock reached a three-month high as retail traders anticipate several July catalysts, including updates on Anktiva's expansion in Saudi Arabia, potential Q2 sales performance, and the company's global manufacturing efforts. The FDA's acceptance of an expa", "url": "https://es.tradingview.com/news/stocktwits:31c110858094b:0-ibrx-stock-at-3-month-high-retail-bulls-eye-july-catalysts-around-anktiva-saudi-expansion-q2-sales/", "source_name": "TradingView", "published_at": "2026-06-30T13:40:23", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ImmunityBio, Inc. SEC Filing", "summary": "ImmunityBio, Inc. (IBRX) filed a Form 144 with the SEC on June 29, 2026, indicating a proposed sale of 95,722 shares of common stock with an aggregate market value of $833,738.62. The shares were acquired through the exercise of stock options on the same date. The filing specifie", "url": "https://www.stocktitan.net/sec-filings/IBRX/144-immunity-bio-inc-sec-filing-d3c9330f23e2.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:13:36", "published_display": "29 Jun 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMWRmNEt1WFFtQVlHWTRTbUNsdVJuRUFNaGFHeTI4MEJReFNpWmJzODd4V3pBT1dQV0NON3lYUThELUZPTzEwMHNPOEFrQ25BQjJFRU11SWZUdjItbm1aa0R0VkNlUHRTc3phaTUxdlEwNGY0Vzg4cExwMDBLUm1GRjdNcTd6TkhuUl8wdE5ZSEx1aDAtU240?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees \u2018Continued Opportunities\u2019 In Immuno-Oncology", "summary": "Sellas Life Sciences (SLS) and ImmunityBio, Inc. (IBRX) are drawing attention as the biotech sector approaches a strong monthly close, with analysts highlighting significant opportunities in immuno-oncology and other cancer treatments. Both companies are seeing their stocks perfo", "url": "https://es.tradingview.com/news/stocktwits:5a9aa46e4094b:0-sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-opportunities-in-immuno-oncology/", "source_name": "TradingView", "published_at": "2026-06-29T04:13:37", "published_display": "29 Jun 2026 04:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article provides a brief financial overview of ImmunityBio, Inc. (NASDAQ: IBRX), focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or a section from a larger financial data platform, indicating key financial data for the company. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:10:27", "published_display": "27 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Simon Barry J. sells $196,907 of common stock", "summary": "ImmunityBio director Simon Barry J. has sold 25,000 shares of the company's common stock for $196,907, with shares sold at an average price of $7.8763. This sale, executed under a Rule 10b5-1 trading plan, follows a significant price appreciation for the stock, though InvestingPr", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-simon-barry-j-sells-196907-of-common-stock-93CH-4763908", "source_name": "Investing.com", "published_at": "2026-06-27T12:39:08", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume", "summary": "ImmunityBio (NASDAQ:IBRX) saw its stock jump 11.8% on Friday, trading with significantly higher volume (41.2 million shares), which was 46% of its past five sessions' trading volume, potentially driven by the Russell reconstitution. Despite a director's planned sale of 25,000 sha", "url": "https://ts2.tech/en/immunitybio-nasdaqibrx-trades-after-post-russell-spike-with-46-more-volume/", "source_name": "TechStock\u00b2", "published_at": "2026-06-27T10:08:00", "published_display": "27 Jun 2026 10:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for ImmunityBio, Inc. (NASDAQ: IBRX). It appears to be an entry from a financial data platform, providing a snapshot of this specific financial ratio for the company. The content itself seems to be a page from ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:46", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunitybio Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Immunitybio Inc. dated June 26. It indicates the latest filing for the company. The article also provides IBRX's stock performance.", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunitybio-inc-for-26-june-93CH-2576802", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T04:10:27", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan", "summary": "ImmunityBio (NASDAQ: IBRX) director Barry J. Simon sold 25,000 shares of common stock on June 24, 2026, at a weighted average price of $7.8763 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, ", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-cbf2a2087dd1.html", "source_name": "Stock Titan", "published_at": "2026-06-27T01:39:46", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ImmunityBio Inc \u2013 SWB:26CA", "summary": "This article provides financial information for ImmunityBio Inc, traded on the Stuttgart Stock Exchange under the symbol SWB:26CA. It specifically focuses on the company's forward price to sales ratio. The content is presented by TradingView, sourcing market data from ICE Data Se", "url": "https://www.tradingview.com/symbols/SWB-26CA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:55", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article provides financial data for ImmunityBio, Inc. (NASDAQ: IBRX), specifically focusing on its forward price-to-sales ratio. It indicates that the current market for this stock is closed and shows no active trades. The page is part of a larger trading platform, offering ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:33", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio stock gains on five new U.S. patent awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPenZDNEdENWdvTV9ZSjFNNUZiY0FLZ01HcUJrV2dMQjE1ejhteGlCekNPZDA3MzM0a2FWNnpDMWtsZ2hfUE9pVWZQVWFHR3A4cFNfdWc1WW1KY1lXX29GNXljZXhPWFdiZnJPZnh3NG9VVnZnQkc1REJEUVBJTHBpQkczY215cG9UNFlheVdoV2xZc25WNmpiNjMzdWVmTkt2QzZTWGFTR21PVWNHR3ZjM29sN2U?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImmunityBio (IBRX) Q1 Loss Of US$632.8 Million Tests Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNajRqLW5YNzJpSFAzV3lMY180QmdkN1k0RnViWmlra2NZUkhLME5reURROU91bnpwU1NSN2QwMVZoV3F2VVJPcmRocVgxbzNEMHhmT3dkVmVtYjdMVk9hWFFuVWtFUjF5SHIwXzdsTS1vVHYtZTBiQmtEWDI2NjRXa2FQNzFWY2ZHWFk0M0dYWGhzTlZacGZPS1RSLXF5dzg3bUVvRENuUjVxV2ttUHdfWHBISFVMdGRPLXBJZTlTTFpVdjltSllSVXhhLXJqUmJTSnFEaTRiZw?oc=5", "source_name": "FinancialContent", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Stock Falls Following FDA Warning Letter Response - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeEw1VTM2WlF5cVozQnVaN2w1UWpDT3JCRkdRNHJXa2V4UkZUaE04SE5Ibkp0WW52R1Vhb284NkFRTDNkaTZLQ25NekJ5Y2d2eEpobFpHVTdKWHJPRlFqMl9yUzJOazNPZVJXdTdzQWpVTWVmNkRTVVBlbmxHZTI4MThKWWxKRzBfVkFHa3gza1VBOTl6c1BGakpIcUhRZGpJQlE?oc=5", "source_name": "IndexBox", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 6, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why ImmunityBio Stock Is Down More Than 20% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNbWRGbC0yQkxwdVFiSU85VGJ2UVI1YmMzVmllOUFmc2N3MVFUamJyYWRjMFJnWHh2ZFpuN0c3SDF4bGdyUjVMX29oODRzVEl4dmtyUkFsbndWN3Fram56MS1aMU9GbmMzUVZBZDY5ZkE5M2NMekdtSkhKdlJTUVpxNA?oc=5", "source_name": "AOL.com", "published_at": "2026-03-24T17:02:03+00:00", "published_display": "24 Mar 2026 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Tumbles 25% on FDA Warning. No, Its Drug Can\u2019t \u2018Treat All Cancers.\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNTHlHMmNFMlYtTG9USld0NE04cHUwelhyZXV6U29sTndRbkJncjJ5WjhCcnhKemxPWldtUlNPT0VTUFlTam1MUUlGRUlaSzJkR1U2SENRaUtJTVN3OU1CQVVFc1ZKa2JtN2NQOWR3SmFCOWJDUnZkTUJWWXgxQ0l3MUZVM25TSzVMS284?oc=5", "source_name": "Barron's", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: ImmunityBio shares drop 20% on FDA warning letter over cancer therapy claims in ad", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSHhNcllLTnNQVXIwR3hkVWtvb1BEQlFWdlRsZ0RwZmQwTGVfWVNFbUxqaHBzbXVKX1pOYV9wMjR1a21GU2hSVmZDVE10YWpCQjg3V1kxT3l5YU11U3RzWDE1SkU4by12eHpVTlRpWm40TVJFbUY4d1JtR1p4YV9oLUVhUlVzdlROV1RCWUJqZXdLRXplb2dNbkJQM3dKRE9OR0g5RUZfOGhnVGhDRlp2ZDVB?oc=5", "source_name": "TradingView", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio\u2019s Stock Sees a Huge Boost", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOLTNWQVhYQzBhal9uY1FtWkZWT0ZqY0hocmxKdjVibkNoNEFFTEFLLW84ajZwcHptRFkzU2pQVFVReGZqLWZFd3gxeFJidHo5Z1pwSFA4WUtGVmRaNmVuYUZFV29sbzA1YjlFWjV3aVI2QVlUdW0wVXg4c3loSnFXLW9KcmM?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here\u2019s What\u2019s Driving the Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPX0xUblM4QmRqbnRDQWlESGZOcGFhNmlibXRqZ0tEbXl2NXA2RFNLZmVISDU0LWJka3hsdHZadUdET3RVcTdpQ3o4LUItVHQtTFd4VmpwZTRQWFFqNVpieHFIbWJiZ05pWTlCM09JVVVmeE5Vbk4zZEJMUnVJc2NKTjdrYk5Xdzl0cHdabXdvQnRPZmxMS3NuZ2lEYXRIakRSUm9qRFgwT0tQM3Z2cjVr?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNR21yRmduUC1McUYwc1hIdGhyVHFDRVdQUU9NVEVQZHNhSnBPY1BXR0hFRDFRNjFDb3Iwd0ZUUnJKUU91aEhJbkRXUlhBR0VjcDJFdjdDT2FRSFIyNFMtbENiYVIyU1A1eXdMWUpmSVIxQVI2X2o0WkszeUNRZHJyTHpjcVNzamxuTzFwZ0lXdGphM0NyT2VUdVlUc2o?oc=5", "source_name": "Finviz", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ImmunityBio Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNQ19kWHF0WEx4R3R4YXBlQXJqcnQzTTdBTXMxbFd4VVRqQ3MtNFl0UkpiNl9pU056dlBObDFKYWdLekxWaVJZREJKWjh4RzhEOWpGNHRLYnlxeUdoSHRsRkJueDQ5TDRVaVhCbVVKZi01N0M0OTBleGRObkF2LUdGeGZ3MFRsaTF2?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTjhMdE12akUwc3RDZGRGemgyaHpvNDJHbGM2M0lTZW94SkJhTWhjT3l1Ml9jUllhZGp0TXFsX1hjWVNZRVZMb3ZFTFA0X2hfd19SUTlsNWVodzJqTkRDbGdGaGJzUzVwSHVUaWJ0RVVLV0VNNDN1aWsxMWU4RUFDY1BuRUxodw?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio And 2 Other Stocks That May Be Priced Below Their Estimated Worth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOVzNjNDY5cXpMcmkwQ0taTEhpVERwUThycXRIaTRSbjRGdXVMRGxBMU51bU9saW1feVJUS1dwMHRPNXlfMnQwaXpWZEdybktOQkxhZjltT1N5M0hZdkR3VE1rZnpHR3pNOThDU0pHYWtOY2pKVTZ2RHBtdUdUZFNld1NR?oc=5", "source_name": "Market source", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Are Surging IBRX Retail Debates Hinting at a Deeper Re\u2011rating of ImmunityBio\u2019s Platform?", "summary": "ImmunityBio (IBRX) is awaiting an FDA decision on its drug Anktiva for bladder cancer, with a PDUFA date of January 6, 2027. This regulatory milestone, combined with increasing retail investor interest, is influencing sentiment around the broader immunotherapy platform. The compa", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/are-surging-ibrx-retail-debates-hinting-at-a-deeper-rerating", "source_name": "Simply Wall Street", "published_at": "2026-07-15T08:12:57", "published_display": "15 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkM0dEVaZkVaOFBTTUVwN08zVGp3MEJ3QXRkZXFhcVNtRmtCWjRNUTRsYk9oR2pLNFdXR0dDN0w4VlBwWVZQcGpaNkNyX2prMHlyNHNrWWQtV19XYkVRMkxXeVJMSm1UVUdQVFBhbkJUUHVBcGtKalN6WDZMVHZoc2RsRGdtc2Z5U09OY3JjVzZmdUNOZHB5SC1mYjJtOW5zcmlUbXBVRVBlenlIYXVCZHlOMzFMNWtTM1EybFNrdWlmNGs?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T15:39:33+00:00", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Climbs Premarket Despite Investor Stake Cut \u2014 Retail Sees \u2018Imminent\u2019 Global Rollout Catalyst", "summary": "ImmunityBio (IBRX) stock rose in premarket trading even after an institutional investor, Sheets Smith Wealth Management, cut its stake. This climb was driven by retail traders anticipating an imminent global rollout announcement for Anktiva, despite the FDA's ongoing review for b", "url": "https://stocktwits.com/news-articles/markets/equity/ibrx-investor-stake-cut-retail-imminent-global-rollout/cZZbqRKR7pg", "source_name": "Stocktwits", "published_at": "2026-07-14T08:12:50", "published_display": "14 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Declines \u2014 ImmunityBio Resubmits Anktiva Application To FDA With Additional Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcWp2SVRmUXBHQjYyQVRaOHdNLXhyam5xZDdaOURRQllzZVNqUEdzdU5HRHFIX3J5SkxtVEx0M0ZqMnN3Q3FUVVJMRDBWTzEtYl8xVzB1TFdIcEpvcmNXb0wxSjhwb1VBQW80ODhlM0pNRjRFVUpyUU96bmtwOXplOFRDZThrejZNOWJOMnFyLTFfQ2hvdDNDZkk1b0FiRml3NDdYVWIwOEZMVmF2VW80d3I2T0lFeFcyenJBRDJMUUhKNGlfRjVtQ0YxV2k?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T11:21:30+00:00", "published_display": "13 Jul 2026 11:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Could Be 37% Below Fair Value Following Revenue Surprise Talk", "summary": "ImmunityBio (IBRX) is gaining attention due to new investment firm positions and speculation about a Q2 revenue surprise and Anktiva label expansion updates. Despite a recent pullback, the stock is up significantly year-to-date and trades below its estimated fair value of $13. Th", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-could-be-37-below-fair-value-following-reve", "source_name": "Simply Wall Street", "published_at": "2026-07-11T18:12:50", "published_display": "11 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise", "summary": "ImmunityBio, Inc. (IBRX) saw its stock rally as institutional investors increased their holdings and retail traders anticipated a strong Q2 revenue surprise, particularly regarding Anktiva sales. Strategic Investment Solutions and Mayflower Financial Advisory significantly raised", "url": "https://es.tradingview.com/news/stocktwits:7cb36081e094b:0-can-ibrx-stock-keep-its-pulse-institutional-investors-buy-in-retail-hopes-for-big-q2-surprise/", "source_name": "TradingView", "published_at": "2026-07-10T18:12:58", "published_display": "10 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout", "summary": "", "url": "https://finance.yahoo.com/m/4a69b719-3b8d-34e5-bd28-3ea282cb0be8/moderna-drops-11%25%2C.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:04:38+00:00", "published_display": "10 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio : IBRX", "summary": "ImmunityBio Inc. (IBRX) is a biotechnology company focused on developing innovative therapies and vaccines for cancers and infectious diseases, including COVID-19 and HIV. The company has a diverse pipeline encompassing immunotherapy, cell therapy, and advanced vaccine technologi", "url": "https://247wallst.com/companies/IBRX/?tpid=1622801&tv=link&tc=in_content", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:08:59", "published_display": "10 Jul 2026 16:08", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares", "summary": "ImmunityBio Inc. (IBRX) stock steadied following the sale of 131,210 shares by director Cheryl Cohen for approximately $1.25 million, though she retains a significant stake. The sale comes as IBRX has experienced a strong multi-week run but faces mounting pressure from clinical t", "url": "https://stockstotrade.com/news/immunitybio-inc-ibrx-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T12:33:00", "published_display": "10 Jul 2026 12:33", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Selecky sells $1.44m in shares", "summary": "ImmunityBio director Christobel Selecky sold 159,478 shares of common stock for $1.44 million on July 1, 2026, after exercising stock options. This sale, conducted via a Rule 10b5-1 trading plan, leaves Ms. Selecky with no direct shares. The company's stock (IBRX) has seen a 305%", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-selecky-sells-144m-in-shares-93CH-4778106", "source_name": "Investing.com", "published_at": "2026-07-07T17:10:22", "published_display": "07 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Cheryl Cohen sells $1.25m in stock", "summary": "ImmunityBio director Cheryl Cohen sold 131,210 shares of the company's common stock for $1.25 million on July 2, 2026, while also acquiring 55,979 shares through stock options. These transactions occurred as ImmunityBio's stock has surged 227% over the past year, though it is con", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-cheryl-cohen-sells-125m-in-stock-93CH-4778108", "source_name": "Investing.com", "published_at": "2026-07-07T16:39:47", "published_display": "07 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-074954528.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:49:54+00:00", "published_display": "07 Jul 2026 07:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-074845085.html", "source_name": "MT Newswires", "published_at": "2026-07-07T07:48:45+00:00", "published_display": "07 Jul 2026 07:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) director trades 131K shares, exercises 55,979 options", "summary": "ImmunityBio, Inc. Director Cheryl Cohen reported an exercise-and-sale transaction involving the company's common stock. On July 2, 2026, she sold 131,210 shares at a weighted average price of $9.5034 per share under a pre-arranged Rule 10b5-1 trading plan. Simultaneously, Cohen e", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-a9f624c8064f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T04:11:37", "published_display": "07 Jul 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst", "summary": "ImmunityBio (IBRX) shares slipped after an independent director filed to sell over 131,000 shares, valued at $1.2 million, which cooled retail sentiment despite the stock's recent gains. Investors are now focused on the potential FDA label expansion for Anktiva for papillary blad", "url": "https://es.tradingview.com/news/stocktwits:6cac2a63a094b:0-ibrx-stock-slips-overnight-insider-sale-tests-retail-optimism-ahead-of-fda-growth-catalyst/", "source_name": "TradingView", "published_at": "2026-07-06T16:13:29", "published_display": "06 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion Efforts - What's Changed", "summary": "ImmunityBio (IBRX) saw an 8.4% stock increase despite being removed from several Russell value benchmarks. The company's investment narrative is largely tied to the expansion of its cancer drug Anktiva beyond its initial bladder cancer niche, with investors closely watching the F", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/immunitybio-ibrx-is-up-84-after-russell-index-removal-amid-a", "source_name": "Simply Wall Street", "published_at": "2026-07-05T04:09:37", "published_display": "05 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX - ImmunityBio Inc Revenue Breakdown", "summary": "This page provides a detailed financial breakdown for ImmunityBio Inc. (IBRX), including its market capitalization, enterprise value, income, sales, key financial ratios, stock performance metrics, and ownership percentages. The data presented covers various aspects of the compan", "url": "https://finviz.com/stock?t=IBRX&ty=rv&ta=0&p=d", "source_name": "Finviz", "published_at": "2026-07-03T14:40:52", "published_display": "03 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Selecky sells $871k in stock", "summary": "ImmunityBio director Christobel Selecky sold approximately $871,215 worth of common stock on June 29 and 30, 2026, through a pre-arranged trading plan. These sales followed the exercise of stock options to acquire shares at a lower price. Following these transactions, Selecky no ", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-selecky-sells-871k-in-stock-93CH-4771698", "source_name": "Investing.com", "published_at": "2026-07-02T02:14:09", "published_display": "02 Jul 2026 02:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunitybio Insider Sold Shares Worth $871,216, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunitybio-insider-sold-shares-worth-210702469.html", "source_name": "MT Newswires", "published_at": "2026-07-01T21:07:02+00:00", "published_display": "01 Jul 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares", "summary": "ImmunityBio, Inc. director Christobel Selecky exercised stock options for 96,722 shares of Common Stock and subsequently sold all of them in pre-planned, open-market transactions on June 29-30, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 20", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-ac4ed0a9453b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:43", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale", "summary": "A Form 144 filing by ImmunityBio, Inc. (IBRX) disclosed an insider's recent stock activities. The filing detailed an exercise of 1,000 shares settled for cash on June 30, 2026, and a prior 10b5-1 sale by Christobel Selecky of 95,722 shares on June 29, 2026, for gross proceeds of ", "url": "https://www.stocktitan.net/sec-filings/IBRX/144-immunity-bio-inc-sec-filing-e46f90cd886f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:04", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales", "summary": "ImmunityBio, Inc. (IBRX) stock reached a three-month high as retail traders anticipate several July catalysts, including updates on Anktiva's expansion in Saudi Arabia, potential Q2 sales performance, and the company's global manufacturing efforts. The FDA's acceptance of an expa", "url": "https://es.tradingview.com/news/stocktwits:31c110858094b:0-ibrx-stock-at-3-month-high-retail-bulls-eye-july-catalysts-around-anktiva-saudi-expansion-q2-sales/", "source_name": "TradingView", "published_at": "2026-06-30T13:40:23", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] ImmunityBio, Inc. SEC Filing", "summary": "ImmunityBio, Inc. (IBRX) filed a Form 144 with the SEC on June 29, 2026, indicating a proposed sale of 95,722 shares of common stock with an aggregate market value of $833,738.62. The shares were acquired through the exercise of stock options on the same date. The filing specifie", "url": "https://www.stocktitan.net/sec-filings/IBRX/144-immunity-bio-inc-sec-filing-d3c9330f23e2.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:13:36", "published_display": "29 Jun 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNMWRmNEt1WFFtQVlHWTRTbUNsdVJuRUFNaGFHeTI4MEJReFNpWmJzODd4V3pBT1dQV0NON3lYUThELUZPTzEwMHNPOEFrQ25BQjJFRU11SWZUdjItbm1aa0R0VkNlUHRTc3phaTUxdlEwNGY0Vzg4cExwMDBLUm1GRjdNcTd6TkhuUl8wdE5ZSEx1aDAtU240?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees \u2018Continued Opportunities\u2019 In Immuno-Oncology", "summary": "Sellas Life Sciences (SLS) and ImmunityBio, Inc. (IBRX) are drawing attention as the biotech sector approaches a strong monthly close, with analysts highlighting significant opportunities in immuno-oncology and other cancer treatments. Both companies are seeing their stocks perfo", "url": "https://es.tradingview.com/news/stocktwits:5a9aa46e4094b:0-sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-opportunities-in-immuno-oncology/", "source_name": "TradingView", "published_at": "2026-06-29T04:13:37", "published_display": "29 Jun 2026 04:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article provides a brief financial overview of ImmunityBio, Inc. (NASDAQ: IBRX), focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or a section from a larger financial data platform, indicating key financial data for the company. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:10:27", "published_display": "27 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio director Simon Barry J. sells $196,907 of common stock", "summary": "ImmunityBio director Simon Barry J. has sold 25,000 shares of the company's common stock for $196,907, with shares sold at an average price of $7.8763. This sale, executed under a Rule 10b5-1 trading plan, follows a significant price appreciation for the stock, though InvestingPr", "url": "https://www.investing.com/news/insider-trading-news/immunitybio-director-simon-barry-j-sells-196907-of-common-stock-93CH-4763908", "source_name": "Investing.com", "published_at": "2026-06-27T12:39:08", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume", "summary": "ImmunityBio (NASDAQ:IBRX) saw its stock jump 11.8% on Friday, trading with significantly higher volume (41.2 million shares), which was 46% of its past five sessions' trading volume, potentially driven by the Russell reconstitution. Despite a director's planned sale of 25,000 sha", "url": "https://ts2.tech/en/immunitybio-nasdaqibrx-trades-after-post-russell-spike-with-46-more-volume/", "source_name": "TechStock\u00b2", "published_at": "2026-06-27T10:08:00", "published_display": "27 Jun 2026 10:08", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for ImmunityBio, Inc. (NASDAQ: IBRX). It appears to be an entry from a financial data platform, providing a snapshot of this specific financial ratio for the company. The content itself seems to be a page from ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:46", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunitybio Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Immunitybio Inc. dated June 26. It indicates the latest filing for the company. The article also provides IBRX's stock performance.", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunitybio-inc-for-26-june-93CH-2576802", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T04:10:27", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan", "summary": "ImmunityBio (NASDAQ: IBRX) director Barry J. Simon sold 25,000 shares of common stock on June 24, 2026, at a weighted average price of $7.8763 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, ", "url": "https://www.stocktitan.net/sec-filings/IBRX/form-4-immunity-bio-inc-insider-trading-activity-cbf2a2087dd1.html", "source_name": "Stock Titan", "published_at": "2026-06-27T01:39:46", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ImmunityBio Inc \u2013 SWB:26CA", "summary": "This article provides financial information for ImmunityBio Inc, traded on the Stuttgart Stock Exchange under the symbol SWB:26CA. It specifically focuses on the company's forward price to sales ratio. The content is presented by TradingView, sourcing market data from ICE Data Se", "url": "https://www.tradingview.com/symbols/SWB-26CA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:55", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of ImmunityBio, Inc. \u2013 NASDAQ:IBRX", "summary": "This article provides financial data for ImmunityBio, Inc. (NASDAQ: IBRX), specifically focusing on its forward price-to-sales ratio. It indicates that the current market for this stock is closed and shows no active trades. The page is part of a larger trading platform, offering ", "url": "https://www.tradingview.com/symbols/NASDAQ-IBRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:33", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio stock gains on five new U.S. patent awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPenZDNEdENWdvTV9ZSjFNNUZiY0FLZ01HcUJrV2dMQjE1ejhteGlCekNPZDA3MzM0a2FWNnpDMWtsZ2hfUE9pVWZQVWFHR3A4cFNfdWc1WW1KY1lXX29GNXljZXhPWFdiZnJPZnh3NG9VVnZnQkc1REJEUVBJTHBpQkczY215cG9UNFlheVdoV2xZc25WNmpiNjMzdWVmTkt2QzZTWGFTR21PVWNHR3ZjM29sN2U?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Q1 Loss Of US$632.8 Million Tests Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNajRqLW5YNzJpSFAzV3lMY180QmdkN1k0RnViWmlra2NZUkhLME5reURROU91bnpwU1NSN2QwMVZoV3F2VVJPcmRocVgxbzNEMHhmT3dkVmVtYjdMVk9hWFFuVWtFUjF5SHIwXzdsTS1vVHYtZTBiQmtEWDI2NjRXa2FQNzFWY2ZHWFk0M0dYWGhzTlZacGZPS1RSLXF5dzg3bUVvRENuUjVxV2ttUHdfWHBISFVMdGRPLXBJZTlTTFpVdjltSllSVXhhLXJqUmJTSnFEaTRiZw?oc=5", "source_name": "FinancialContent", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio (IBRX) Stock Falls Following FDA Warning Letter Response - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeEw1VTM2WlF5cVozQnVaN2w1UWpDT3JCRkdRNHJXa2V4UkZUaE04SE5Ibkp0WW52R1Vhb284NkFRTDNkaTZLQ25NekJ5Y2d2eEpobFpHVTdKWHJPRlFqMl9yUzJOazNPZVJXdTdzQWpVTWVmNkRTVVBlbmxHZTI4MThKWWxKRzBfVkFHa3gza1VBOTl6c1BGakpIcUhRZGpJQlE?oc=5", "source_name": "IndexBox", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 6, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ImmunityBio Stock Is Down More Than 20% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNbWRGbC0yQkxwdVFiSU85VGJ2UVI1YmMzVmllOUFmc2N3MVFUamJyYWRjMFJnWHh2ZFpuN0c3SDF4bGdyUjVMX29oODRzVEl4dmtyUkFsbndWN3Fram56MS1aMU9GbmMzUVZBZDY5ZkE5M2NMekdtSkhKdlJTUVpxNA?oc=5", "source_name": "AOL.com", "published_at": "2026-03-24T17:02:03+00:00", "published_display": "24 Mar 2026 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Tumbles 25% on FDA Warning. No, Its Drug Can\u2019t \u2018Treat All Cancers.\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNTHlHMmNFMlYtTG9USld0NE04cHUwelhyZXV6U29sTndRbkJncjJ5WjhCcnhKemxPWldtUlNPT0VTUFlTam1MUUlGRUlaSzJkR1U2SENRaUtJTVN3OU1CQVVFc1ZKa2JtN2NQOWR3SmFCOWJDUnZkTUJWWXgxQ0l3MUZVM25TSzVMS284?oc=5", "source_name": "Barron's", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: ImmunityBio shares drop 20% on FDA warning letter over cancer therapy claims in ad", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSHhNcllLTnNQVXIwR3hkVWtvb1BEQlFWdlRsZ0RwZmQwTGVfWVNFbUxqaHBzbXVKX1pOYV9wMjR1a21GU2hSVmZDVE10YWpCQjg3V1kxT3l5YU11U3RzWDE1SkU4by12eHpVTlRpWm40TVJFbUY4d1JtR1p4YV9oLUVhUlVzdlROV1RCWUJqZXdLRXplb2dNbkJQM3dKRE9OR0g5RUZfOGhnVGhDRlp2ZDVB?oc=5", "source_name": "TradingView", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio\u2019s Stock Sees a Huge Boost", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOLTNWQVhYQzBhal9uY1FtWkZWT0ZqY0hocmxKdjVibkNoNEFFTEFLLW84ajZwcHptRFkzU2pQVFVReGZqLWZFd3gxeFJidHo5Z1pwSFA4WUtGVmRaNmVuYUZFV29sbzA1YjlFWjV3aVI2QVlUdW0wVXg4c3loSnFXLW9KcmM?oc=5", "source_name": "Los Angeles Business Journal", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here\u2019s What\u2019s Driving the Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPX0xUblM4QmRqbnRDQWlESGZOcGFhNmlibXRqZ0tEbXl2NXA2RFNLZmVISDU0LWJka3hsdHZadUdET3RVcTdpQ3o4LUItVHQtTFd4VmpwZTRQWFFqNVpieHFIbWJiZ05pWTlCM09JVVVmeE5Vbk4zZEJMUnVJc2NKTjdrYk5Xdzl0cHdabXdvQnRPZmxMS3NuZ2lEYXRIakRSUm9qRFgwT0tQM3Z2cjVr?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNR21yRmduUC1McUYwc1hIdGhyVHFDRVdQUU9NVEVQZHNhSnBPY1BXR0hFRDFRNjFDb3Iwd0ZUUnJKUU91aEhJbkRXUlhBR0VjcDJFdjdDT2FRSFIyNFMtbENiYVIyU1A1eXdMWUpmSVIxQVI2X2o0WkszeUNRZHJyTHpjcVNzamxuTzFwZ0lXdGphM0NyT2VUdVlUc2o?oc=5", "source_name": "Finviz", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ImmunityBio Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNQ19kWHF0WEx4R3R4YXBlQXJqcnQzTTdBTXMxbFd4VVRqQ3MtNFl0UkpiNl9pU056dlBObDFKYWdLekxWaVJZREJKWjh4RzhEOWpGNHRLYnlxeUdoSHRsRkJueDQ5TDRVaVhCbVVKZi01N0M0OTBleGRObkF2LUdGeGZ3MFRsaTF2?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOTjhMdE12akUwc3RDZGRGemgyaHpvNDJHbGM2M0lTZW94SkJhTWhjT3l1Ml9jUllhZGp0TXFsX1hjWVNZRVZMb3ZFTFA0X2hfd19SUTlsNWVodzJqTkRDbGdGaGJzUzVwSHVUaWJ0RVVLV0VNNDN1aWsxMWU4RUFDY1BuRUxodw?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmunityBio And 2 Other Stocks That May Be Priced Below Their Estimated Worth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOVzNjNDY5cXpMcmkwQ0taTEhpVERwUThycXRIaTRSbjRGdXVMRGxBMU51bU9saW1feVJUS1dwMHRPNXlfMnQwaXpWZEdybktOQkxhZjltT1N5M0hZdkR3VE1rZnpHR3pNOThDU0pHYWtOY2pKVTZ2RHBtdUdUZFNld1NR?oc=5", "source_name": "Market source", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 56, "sentiment_summary": {"positive": 13, "negative": 10, "neutral": 33, "score": 51, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 8.22, "latest_week": "2026-07-10", "one_week_move": -12.9, "four_week_move": 15.8, "twelve_week_move": 6.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.070144, "market_dynamics_buy_signal": false, "relative_strength": 44.297859, "fair_value_gap": 93.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.9064, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-12.9% over one week, +15.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 8}, {"label": "Investing.com", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "Stocktwits", "count": 3}, {"label": "MT Newswires", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-12.9% over one week, +15.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Are Surging IBRX Retail Debates Hinting at a Deeper Re\u2011rating of ImmunityBio\u2019s Platform?"}], "updated_at": "2026-07-16T06:04:45.963528+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}